HIND Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

2.819

Open

2.580

VWAP

2.65

Vol

29.87K

Mkt Cap

14.56M

Low

2.550

Amount

79.15K

EV/EBITDA(TTM)

--

Total Shares

5.64M

EV

10.36M

EV/OCF(TTM)

--

P/S(TTM)

0.96

Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.

Show More

Events Timeline

(ET)

2026-02-18

09:10:00

Vyome Holdings Publishes Preclinical Data for VT-1908

2026-02-11 (ET)

2026-02-11

07:30:00

Vyome Holdings Files for Orphan Drug Status for VT-1953

2025-12-08 (ET)

2025-12-08

08:20:00

Vyome Holdings VT-1953 Clinical Trial Success

2025-09-29 (ET)

2025-09-29

07:34:29

Vyome Holdings Purchases Oculo Health, an AI Spinout from MIT

2025-09-17 (ET)

2025-09-17

07:13:19

Vyome Holdings Reveals Findings from Preclinical Studies of VT-1908

2025-09-09 (ET)

2025-09-09

09:05:53

Vyome Holdings names Richard Fahrner as Chief Technology Officer

News

Newsfilter

02-18Newsfilter

Vyome Publishes Preclinical Data for VT-1908

Businesswire

2025-12-31Businesswire

Harvest Announces 2025 ETF Reinvested Distributions

Newsfilter

2025-12-31Newsfilter

Harvest Announces Final Annual Reinvested Distributions for 2025 Tax Year

Businesswire

2025-12-22Businesswire

Harvest ETFs Updates 2025 Estimated Reinvested Distributions

Newsfilter

2025-12-08Newsfilter

Vyome's VT-1953 Treatment Significantly Improves Malodor in Malignant Wounds

Newsfilter

2025-11-21Newsfilter

Harvest ETFs Reveals Distribution Plans for November 2025

1 Analyst Rating

Wall Street analysts forecast HIND stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

15.00

Averages

15.00

High

15.00

Current: 0.000

Low

15.00

Averages

15.00

High

15.00

No data

No data

Valuation Metrics

The current forward P/E ratio for Vyome Holdings Inc (HIND.O) is -3.78, compared to its 5-year average forward P/E of -8.11. For a more detailed relative valuation and DCF analysis to assess Vyome Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-8.11

Current PE

-3.78

Overvalued PE

-2.67

Undervalued PE

-13.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Whales Holding HIND

Romulus Capital Management, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Vyome Holdings Inc (HIND) stock price today?

The current price of HIND is 2.58 USD — it has decreased -0.77

What is Vyome Holdings Inc (HIND)'s business?

Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.

What is the price predicton of HIND Stock?

Wall Street analysts forecast HIND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIND is15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Vyome Holdings Inc (HIND)'s revenue for the last quarter?

Vyome Holdings Inc revenue for the last quarter amounts to 34.63K USD, decreased -98.49

What is Vyome Holdings Inc (HIND)'s earnings per share (EPS) for the last quarter?

Vyome Holdings Inc. EPS for the last quarter amounts to -3.06 USD, decreased -99.02

How many employees does Vyome Holdings Inc (HIND). have?

Vyome Holdings Inc (HIND) has 17 emplpoyees as of March 12 2026.

What is Vyome Holdings Inc (HIND) market cap?

Today HIND has the market capitalization of 14.56M USD.